Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NCF1 | P14598 | 2/20 | 0.44 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | F12 | P00748 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31416835 | 1.00 | KDM4E (1.00) | KDM4ECYP3A4GAAPDPK1GPR3 | |
| SCHEMBL2578812 | 0.84 | KDM4E (0.71) | KDM4EGPR3ALDH1A1HSD17B10HPGD | |
| SCHEMBL30451373 | 0.84 | KDM4E (0.71) | KDM4EGPR3ALDH1A1HSD17B10HPGD | |
| SCHEMBL2020349 | 0.84 | KDM4E (0.71) | KDM4ECYP3A4GAAPDPK1ALDH1A1 | |
| SCHEMBL31132418 | 0.81 | KDM4E (0.65) | KDM4EALDH1A1MAPTSMARCA2SMARCA4 | |
| SCHEMBL219856 | 0.81 | KDM4E (0.65) | KDM4EALDH1A1MAPTSMARCA2SMARCA4 | |
| SCHEMBL15721355 | 0.81 | ALDH1A1 (0.78) | KDM4ECYP3A4GAAPDPK1ALDH1A1 | |
| SCHEMBL30014143 | 0.79 | KDM4E (0.62) | KDM4ECYP3A4GAAPDPK1ALDH1A1 | |
| SCHEMBL30453263 | 0.79 | KDM4E (0.62) | KDM4ECYP3A4GAAPDPK1ALDH1A1 | |
| SCHEMBL2946369 | 0.79 | KDM4E (0.62) | KDM4ECYP3A4GAAPDPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4349671-A | Process for the production of metal complexes of isoindoline azines | CIBA-GEIGY CORPORATION (US) | 1982-09-14 | — | — | US | claimed |
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12304915-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC (US) | 2014-11-13 | — | — | US | disclosed |
| US-8728453-B2 | Combinatorial polymeric compositions for drug delivery | INNOVOTECH, LLC (US) | 2014-05-20 | — | — | US | disclosed |
| US-8557816-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8330039-B2 | Solar cell modules with poly(vinyl butyral) encapsulant comprising unsaturated heterocyclic compound | E I DU PONT DE NEMOURS AND COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2402329-A1 | Analgetic phenylsulphonamides | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| EP-0036835-B1 | PROCESS FOR THE PREPARATION OF METAL COMPLEXES OF ISOINDOLINE AZINES | CIBA-GEIGY AG (CH) | 1983-09-28 | — | — | EP | disclosed |
| US-4385174-A | FOR PIGMENTS | CIBA-GEIGY CORPORATION (US) | 1983-05-24 | — | — | US | disclosed |
| US-4349671-A | Process for the production of metal complexes of isoindoline azines | CIBA-GEIGY CORPORATION (US) | 1982-09-14 | — | — | US | disclosed |
| EP-0036835-A1 | Process for the preparation of metal complexes of isoindoline azines | CIBA-GEIGY AG (CH) | 1981-09-30 | — | — | EP | disclosed |
| EP-0036834-A1 | Process for the preparation of metal complexes of isoindoline azines | CIBA-GEIGY AG (CH) | 1981-09-30 | — | — | EP | disclosed |
| EP-0036387-A2 | Process for the preparation of hydrazono-isoindolines | CIBA-GEIGY AG (CH) | 1981-09-23 | — | — | EP | disclosed |
| EP-0036388-A2 | Isoindoline derivatives, process for their preparation and their use | CIBA-GEIGY AG (CH) | 1981-09-23 | — | — | EP | disclosed |
| US-4289772-A | PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 1981-09-15 | — | — | US | disclosed |
| US-3878211-A | Process for the manufacture of 1,4-diaminophthaiazine | DYNAMIT NOBEL AG | 1975-04-15 | — | — | US | disclosed |
| US-3878211-A | Process for the manufacture of 1,4-diaminophthaiazine | DYNAMIT NOBEL AG | 1975-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, CDK1 | KDM4E 1131/4885CYP3A4 3294/4885GAA 1887/4885 |
| US-12304915-B2 | SOS1 inhibitors | SOS1, SOS2, SAV1 | KDM4E 3245/4885CYP3A4 4860/4885GAA 2747/4885 |
| US-20230137886-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | KDM4E 3245/4885CYP3A4 4860/4885GAA 2747/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | KDM4E 3245/4885CYP3A4 4860/4885GAA 2747/4885 |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | KDM4E 1131/4885CYP3A4 3294/4885GAA 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.